Case Report: Temporal dissociation between peripheral B-cell pharmacodynamics and renal remission during sequential rituximab and telitacicept-containing therapy in childhood secondary steroid-resistant nephrotic syndrome
- 1Department of Nephrology, Jiangxi Provincial Children’s Hospital
Abstract
Rituximab (RTX) can improve outcomes in children with frequently relapsing or steroid-dependent nephrotic syndrome, although a marked reduction in circulating B cells does not invariably coincide with renal remission. We report a girl who developed frequently relapsing/steroid-dependent nephrotic syndrome after an initial steroid-sensitive course, with kidney biopsy findings supporting minimal change disease. Following a relapse in 2024, persistent nephrotic-range proteinuria despite infection control and 4 weeks of standard-dose prednisone plus tacrolimus led to classification as secondary steroid-resistant nephrotic syndrome. She subsequently received two RTX infusions of 375 mg/m² (340 mg) 49 days apart. The last available pre-RTX peripheral CD19-positive B-cell count was 99.78 cells/μL and was 1.63 cells/μL 13 days after the first infusion; it had risen to 10.43 cells/μL immediately before the second infusion, and then decreased again to 1.29 cells/μL; however, proteinuria persisted. Telitacicept 80 mg once weekly was added to prednisone and tacrolimus on December 11, 2024. Peripheral B-cell reconstitution had begun before complete remission, and urine protein became negative 91 days after telitacicept initiation and 132 days after the second RTX infusion. Telitacicept was discontinued in May 2025 because of financial constraints, but remission was maintained. A transient increase in proteinuria during a respiratory tract infection subsequently resolved without restarting telitacicept. No serious treatment-related reactions were observed. This case illustrates a temporal dissociation between measured peripheral CD19-positive B-cell pharmacodynamics after RTX and complete renal remission. Remission was documented later during telitacicept-containing therapy; however, the prolonged RTX dosing interval, uncertain early RTX exposure, continued prednisone and tacrolimus, and natural disease fluctuations preclude causal attribution to telitacicept and do not establish biological RTX resistance. These observations support prospective evaluation of peripheral and tissue B-cell kinetics, RTX pharmacokinetics, and sequential CD20 and BAFF/APRIL targeting.
Related
- CSF pharmacokinetics-pharmacodynamics of linezolid in critically brain injured patients, with or without central nervous system healthcare-associated infection. The PK-Pop-LCR Study: A Multicentre Pharmacokinetics and Pharmacodynamics Population Study
- Meta-Analysis and Physiologically-Based Modeling of the Pharmacokinetics and Pharmacodynamics of Dexamethasone in Horses
- Safety, pharmacokinetics and pharmacodynamics of ICP-332, an oral TYK2 inhibitor, in healthy participants: a randomized, double-blind, placebo-controlled phase I study
- Perceptual repulsion and decisional attraction in male body serial dependence: a dimensional dissociation in channel architecture
- In search of Perruchet’s dissociation between expectancy and control in the flanker task
BibTeX
@article{hu2026case,
title = {{Case Report: Temporal dissociation between peripheral B-cell pharmacodynamics and renal remission during sequential rituximab and telitacicept-containing therapy in childhood secondary steroid-resistant nephrotic syndrome}},
author = {Shaofan Hu and Qun Li and Haifeng Qi and Weimin Zheng and Xiaojie Peng and Rui Fu},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1958047},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1958047/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Temporal dissociation between peripheral B-cell pharmacodynamics and renal remission during sequential rituximab and telitacicept-containing therapy in childhood secondary steroid-resistant nephrotic syndrome
AU - Shaofan Hu
AU - Qun Li
AU - Haifeng Qi
AU - Weimin Zheng
AU - Xiaojie Peng
AU - Rui Fu
PY - 2026
DA - 2026/10/20
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1958047
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1958047/full
AB - Rituximab (RTX) can improve outcomes in children with frequently relapsing or steroid-dependent nephrotic syndrome, although a marked reduction in circulating B cells does not invariably coincide with renal remission. We report a girl who developed frequently relapsing/steroid-dependent nephrotic syndrome after an initial steroid-sensitive course, with kidney biopsy findings supporting minimal change disease. Following a relapse in 2024, persistent nephrotic-range proteinuria despite infection control and 4 weeks of standard-dose prednisone plus tacrolimus led to classification as secondary steroid-resistant nephrotic syndrome. She subsequently received two RTX infusions of 375 mg/m² (340 mg) 49 days apart. The last available pre-RTX peripheral CD19-positive B-cell count was 99.78 cells/μL and was 1.63 cells/μL 13 days after the first infusion; it had risen to 10.43 cells/μL immediately before the second infusion, and then decreased again to 1.29 cells/μL; however, proteinuria persisted. Telitacicept 80 mg once weekly was added to prednisone and tacrolimus on December 11, 2024. Peripheral B-cell reconstitution had begun before complete remission, and urine protein became negative 91 days after telitacicept initiation and 132 days after the second RTX infusion. Telitacicept was discontinued in May 2025 because of financial constraints, but remission was maintained. A transient increase in proteinuria during a respiratory tract infection subsequently resolved without restarting telitacicept. No serious treatment-related reactions were observed. This case illustrates a temporal dissociation between measured peripheral CD19-positive B-cell pharmacodynamics after RTX and complete renal remission. Remission was documented later during telitacicept-containing therapy; however, the prolonged RTX dosing interval, uncertain early RTX exposure, continued prednisone and tacrolimus, and natural disease fluctuations preclude causal attribution to telitacicept and do not establish biological RTX resistance. These observations support prospective evaluation of peripheral and tissue B-cell kinetics, RTX pharmacokinetics, and sequential CD20 and BAFF/APRIL targeting.
SN - 1664-3224
ER -